AGP Executive Report
Last update: 9 hours agoRett syndrome breakthrough: The EU’s CHMP has issued a positive opinion for Neuren Pharmaceuticals’ DAYBU (trofinetide), recommending marketing authorization for neurobehavioral symptoms of Rett syndrome in adults and children aged five and up—now awaiting a final European Commission decision. Bladder cancer options expand: The European Commission approved Merck/MSD’s Keytruda plus Padcev perioperative regimen for adults with resectable muscle-invasive bladder cancer who can’t receive cisplatin, with trial results showing major improvements in event-free and overall survival. Breast cancer advance: Gilead’s Trodelvy (sacituzumab govitecan) won EU marketing authorization as first-line monotherapy for unresectable or metastatic triple-negative breast cancer in patients not eligible for PD-1/PD-L1 therapy. Cross-border care made clearer: A guide explains how cross-border healthcare works across Europe, including when prior authorization is needed and what costs may be covered. Travel health & safety: UK guidance warns travellers returning from the EU that bringing certain meat and dairy products is illegal and can lead to confiscation and fines. Heat and schools: Record European heat is forcing school closures or shortened days, with limited cooling in many classrooms.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
